| LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research (NCT02231164) | Boehringer Ingelheim | 2014-10-14 |
| Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer (NCT02271581) | Leo W. Jenkins Cancer Center | 2014-10-01 |
| A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System (NCT02370303) | Mayo Clinic | 2014-08-01 |
| Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer (NCT02083679) | EMD Serono | 2014-07-01 |
| Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers (NCT02098954) | Hunan Province Tumor Hospital | 2014-07-01 |
| Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer (NCT02018523) | Jun Zhang | 2014-06-01 |
| Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers (NCT02166242) | Hunan Province Tumor Hospital | 2014-06-01 |
| Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer (NCT02172846) | Washington University School of Medicine | 2014-05-22 |
| Long-term Observation PMS for Afatinib (NCT02131259) | Boehringer Ingelheim | 2014-05-07 |
| A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma (NCT02146118) | MedicalLogic | 2014-04-01 |
| A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) (NCT02079636) | Eli Lilly and Company | 2014-03-28 |
| MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). (NCT02088112) | MedImmune LLC | 2014-03-24 |
| GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations (NCT02047903) | Boehringer Ingelheim | 2014-03-05 |
| Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations (NCT02044380) | Boehringer Ingelheim | 2014-03-01 |
| Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer (NCT02049151) | EMD Serono | 2014-03-01 |
| Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers (NCT02161991) | Hunan Province Tumor Hospital | 2014-02-01 |
| Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population (NCT02000531) | Hoffmann-La Roche | 2014-01-01 |
| Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy (NCT02004184) | Norwegian University of Science and Technology | 2013-12-01 |
| Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (NCT01999673) | Peregrine Pharmaceuticals | 2013-12-01 |
| A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body (NCT02014116) | Eli Lilly and Company | 2013-11-26 |
| Treatment of Multifocal Lung Adenocarcinoma (NCT01946100) | Mayo Clinic | 2013-11-06 |
| Nodal Upstaging in VATS Anatomical Resections for NSCLC (NCT01985659) | University Hospital, Gasthuisberg | 2013-11-01 |
| Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation (NCT01953913) | Boehringer Ingelheim | 2013-09-30 |
| A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (NCT01897480) | Eli Lilly and Company | 2013-08-28 |
| A Study Of PF-06263507 In Patients With Advanced Solid Tumors (NCT01891669) | Pfizer | 2013-08-08 |
| A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants (NCT01900652) | Eli Lilly and Company | 2013-08-01 |
| An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) (NCT01853826) | Boehringer Ingelheim | 2013-07-17 |
| Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer (NCT01909752) | UbiVac | 2013-07-01 |
| A Study of rSIFN-co in Subjects With Advanced Solid Tumors (NCT02387307) | Sichuan Huiyang Life Science and Technology Corporation | 2013-07-01 |
| Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC (NCT01761240) | Morphotek | 2013-06-19 |
| An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1) (NCT01684111) | Aktion Bronchialkarzinom e.V. | 2013-06-01 |
| ADAM-Afatinib Diarrhea Assessment and Management (NCT01814553) | Boehringer Ingelheim | 2013-04-01 |
| Palliative Thoracic Radiotherapy Plus BKM120 (NCT02128724) | University of Oxford | 2013-04-01 |
| An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2) (NCT01683682) | Aktion Bronchialkarzinom e.V. | 2013-04-01 |
| A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI (NCT03050437) | Samsung Medical Center | 2013-03-01 |
| Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients (NCT01415011) | University College, London | 2012-12-01 |
| Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC (NCT01740804) | Guangdong Association of Clinical Trials | 2012-11-01 |
| Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer (NCT01717482) | Mayo Clinic | 2012-10-01 |
| Healthy Directions After Lung Surgery Pilot (NCT02135211) | Dana-Farber Cancer Institute | 2012-09-01 |
| Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. (NCT01652469) | ETOP IBCSG Partners Foundation | 2012-08-01 |
| Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer (NCT01494415) | First People's Hospital of Hangzhou | 2012-07-01 |
| Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer (NCT01637376) | University of Arkansas | 2012-07-01 |
| A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations (NCT01647711) | Boehringer Ingelheim | 2012-07-01 |
| Afatinib Expanded Access Program (NCT01649284) | Boehringer Ingelheim | 2012-07-01 |
| Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (NCT02629848) | Takeda | 2012-07-01 |
| Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases (NCT01823003) | Institut Català d'Oncologia | 2012-06-01 |
| Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer (NCT01671332) | University of Wisconsin, Madison | 2012-06-01 |
| A Study of LY2875358 in Japanese Participants With Advanced Cancer (NCT01602289) | Eli Lilly and Company | 2012-06-01 |
| Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation (NCT01514864) | Bristol-Myers Squibb | 2012-05-31 |
| 18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma (NCT01610544) | National Cancer Institute (NCI) | 2012-05-10 |
| Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer (NCT01545947) | Celgene | 2012-05-01 |
| Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. (NCT01578551) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-05-01 |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings (NCT01700582) | Intergroupe Francophone de Cancerologie Thoracique | 2012-04-01 |
| LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy (NCT01523587) | Boehringer Ingelheim | 2012-03-05 |
| A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) (NCT01469000) | Eli Lilly and Company | 2012-02-01 |
| KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy (NCT01487174) | Kadmon Corporation, LLC | 2011-12-14 |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors (NCT01478685) | Celgene | 2011-11-29 |
| A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients (NCT01444118) | Bioven Europe | 2011-11-01 |
| Study Of Use Of Pemetrexed In Patients With Non-Small Lung Cancer Metastatic In Andalusian Public Health System (NCT01877902) | Fundación Pública Andaluza Progreso y Salud | 2011-10-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) (NCT01449461) | Ariad Pharmaceuticals | 2011-09-20 |
| Molecular Analysis of Thoracic Malignancies (NCT01385722) | Stanford University | 2011-08-01 |
| AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer (NCT01233687) | Ahmad Tarhini | 2011-08-01 |
| Amatuximab for High Mesothelin Cancers (NCT01413451) | National Cancer Institute (NCI) | 2011-07-12 |
| Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG) (NCT01419587) | University of Iowa | 2011-07-01 |
| TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer (NCT01282151) | Chonnam National University Hospital | 2011-07-01 |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab (NCT01307267) | Pfizer | 2011-06-21 |
| A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations (NCT01153984) | Hoffmann-La Roche | 2011-06-01 |
| A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. (NCT01346540) | Boehringer Ingelheim | 2011-04-14 |
| To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer (NCT01284348) | Merck Sharp & Dohme LLC | 2011-03-25 |
| Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring (NCT01326767) | Central European Society for Anticancer Drug Research | 2011-03-01 |
| Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies (NCT01306045) | National Cancer Institute (NCI) | 2011-02-08 |
| A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment (NCT01497041) | Korean South West Oncology Group | 2011-02-01 |
| Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy (NCT01319669) | Chinese Society of Lung Cancer | 2011-02-01 |
| Chemotherapy of NSCLC With or Without Icotinib (NCT02430974) | Nanfang Hospital, Southern Medical University | 2011-01-01 |
| Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer (NCT01261299) | University of California, Davis | 2010-12-01 |
| An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation (NCT01260480) | Aposense Ltd. | 2010-12-01 |
| Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung (NCT01236716) | Chinese Society of Lung Cancer | 2010-11-01 |
| A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT01160744) | Eli Lilly and Company | 2010-09-01 |
| A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer (NCT00697060) | AmpliMed Corporation | 2010-08-01 |
| Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer (NCT00907504) | Pfizer | 2010-07-01 |
| A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples (NCT01382992) | Peking Union Medical College Hospital | 2010-06-01 |
| CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) (NCT01199068) | Daiichi Sankyo Co., Ltd. | 2010-06-01 |
| A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations (NCT01131429) | Chinese PLA General Hospital | 2010-06-01 |
| BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) (NCT01121393) | Boehringer Ingelheim | 2010-04-19 |
| Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer (NCT01088620) | WiSP Wissenschaftlicher Service Pharma GmbH | 2010-04-01 |
| Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer (NCT01090011) | Boehringer Ingelheim | 2010-03-01 |
| CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) (NCT01199055) | Daiichi Sankyo Co., Ltd. | 2010-03-01 |
| Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC) (NCT01079520) | Samsung Medical Center | 2010-03-01 |
| LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (NCT01085136) | Boehringer Ingelheim | 2010-02-01 |
| A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NCT00994123) | Merrimack Pharmaceuticals | 2010-02-01 |
| Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer (NCT00934076) | University of Alabama at Birmingham | 2010-02-01 |
| A Phase 1 Study in Participants With Advanced Cancer (NCT01115790) | Eli Lilly and Company | 2010-02-01 |
| Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC (NCT01088906) | Spanish Lung Cancer Group | 2010-01-01 |
| A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers (NCT01034748) | Pfizer | 2010-01-01 |
| An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene (NCT00932451) | Pfizer | 2010-01-01 |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer (NCT01039948) | AVEO Pharmaceuticals, Inc. | 2009-12-01 |
| Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer (NCT01004419) | University of Wisconsin, Madison | 2009-11-01 |
| Gene Mutations in Non-Small Cell Lung Cancer Cells (NCT00977509) | National Taiwan University Hospital | 2009-11-01 |
| BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC) (NCT00979576) | Boehringer Ingelheim | 2009-10-16 |
| Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer (NCT00973310) | Tianjin Medical University Cancer Institute and Hospital | 2009-10-01 |